Application of near-infrared dyes for tumor imaging, photothermal, and photodynamic therapies

Journal of Pharmaceutical Sciences

Volumn 102, Issue 1, 2013, Pages 6-28

  Yuan, Ahu ^a   Wu, Jinhui ^a   Tang, Xiaolei ^a   Zhao, Lili ^a   Xu, Feng ^b   Hu, Yiqiao ^a  

^a NANJING UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cancer; Drug delivery systems; Nanoparticles; Near infrared spectroscopy; Polymeric drug carrier; Probe substrates; Toxicity

Indexed keywords

ALBUMIN; AMINOLEVULINIC ACID; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CATHEPSIN D; CETUXIMAB; CY5.5 DYE; CYANINE DYE; DYE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUORESCENT DYE; GLIONLAN; INDOCYANINE GREEN; IODIDE IR 730; LIGAND; MACROGOL; MATRILYSIN; NANOPARTICLE; NEAR INFRARED DYE; NIRQ 820; PORPHYRAZINE 247; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN; QSY7; TETRAMETHYLRHODAMINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR;

BIOCOMPATIBILITY; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ENDOSOME; FLUORESCENCE IMAGING; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HYDROPHOBICITY; ILLUMINATION; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOLECULAR PROBE; NANOPROBE; NEAR INFRARED SPECTROSCOPY; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PHOTOTHERAPY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN CLEAVAGE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR CELL;

EID: 84870714194     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23356     Document Type: Review

References (129)

1. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29.
2. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. 2012. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220-241.
3. Lal S, Clare SE, Halas NJ. 2008. Nanoshell-enabled photothermal cancer therapy: Impending clinical impact. Acc Chem Res 41(12):1842-1851.
4. Zhou XJ, Leeds NE, McKinnon GC, Kumar AJ. 2002. Characterization of benign and metastatic vertebral compression fractures with quantitative diffusion MR imaging. AJNR Am J Neuroradiol 23(1):165-170.
5. Janib SM, Moses AS, MacKay JA. 2010. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 62(11):1052-1063.
6. Luo S, Zhang E, Su Y, Cheng T, Shi C. 2011. A review of NIR dyes in cancer targeting and imaging. Biomaterials 32(29):7127-7138.
7. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. 2012. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets.
8. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. 2007. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22.
9. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. 2012. Radiation-induced reprogramming of breast cancer cells. Stem Cells 30(5):833-844.
10. Frangioni JV. 2003. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 7(5):626-634.
11. Carpin LB, Bickford LR, Agollah G, Yu TK, Schiff R, Li Y, Drezek RA. 2011. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat 125(1):27-34.
12. Burke A, Ding X, Singh R, Kraft RA, Levi-Polyachenko N, Rylander MN, Szot C, Buchanan C, Whitney J, Fisher J, Hatcher HC, Jr. D'Agostino R, Kock ND, Ajayan PM, Carroll DL, Akman S, Torti FM, Torti SV. 2009. Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A 106(31):12897-12902.
13. Liu H, Chen D, Li L, Liu T, Tan L, Wu X, Tang F. 2011. Multifunctional gold nanoshells on silica nanorattles: A platform for the combination of photothermal therapy and chemotherapy with low systemic toxicity. Angew Chem Int Ed Engl 50(4):891-895.
14. Capella MA, Capella LS. 2003. A light in multidrug resistance: Photodynamic treatment of multidrug-resistant tumors. J Biomed Sci 10(4):361-366.
15. Zhang C, Liu T, Su Y, Luo S, Zhu Y, Tan X, Fan S, Zhang L, Zhou Y, Cheng T, Shi C. 2010. A near-infrared fluorescent heptamethine indocyanine dye with preferential tumor accumulation for in vivo imaging. Biomaterials 31(25):6612-6617.
16. Wischke C, Schwendeman SP. 2008. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 364(2):298-327.
17. Yang X, Shi C, Tong R, Qian W, Zhau HE, Wang R, Zhu G, Cheng J, Yang VW, Cheng T, Henary M, Strekowski L, Chung LW. 2010. Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res 16(10):2833-2844.
18. Tan X, Luo S, Wang D, Su Y, Cheng T, Shi C. 2012. A NIR heptamethine dye with intrinsic cancer targeting, imaging and photosensitizing properties. Biomaterials 33(7):2230-2239.
19. Trivedi ER, Harney AS, Olive MB, Podgorski I, Moin K, Sloane BF, Barrett AG, Meade TJ, Hoffman BM. 2010. Chiral porphyrazine near-IR optical imaging agent exhibiting preferential tumor accumulation. Proc Natl Acad Sci U S A 107(4):1284-1288.
20. Chen X, Conti PS, Moats RA. 2004. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 64(21):8009-8014.
21. Garanger E, Boturyn D, Dumy P. 2007. Tumor targeting with RGD peptide ligands-Design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 7(5):552-558.
22. Jin ZH, Josserand V, Foillard S, Boturyn D, Dumy P, Favrot MC, Coll JL. 2007. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors. Mol Cancer 6:41.
23. Garanger E, Boturyn D, Jin Z, Dumy P, Favrot MC, Coll JL. 2005. New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors. Mol Ther 12(6):1168-1175.
24. Sancey L, Garanger E, Foillard S, Schoehn G, Hurbin A, Albiges-Rizo C, Boturyn D, Souchier C, Grichine A, Dumy P, Coll JL. 2009. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther 17(5):837-843.
25. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. 2006. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118(5):1173-1180.
26. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C. 2003. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 63(22):7870-7875.
27. Soukos NS, Hamblin MR, Keel S, Fabian RL, Deutsch TF, Hasan T. 2001. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 61(11):4490-4496.
28. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG. 2011. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 52(11):1778-1785.
29. Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, Pomper MG. 2009. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 390(3):624-629.
30. Ghoroghchian PP, Frail PR, Susumu K, Blessington D, Brannan AK, Bates FS, Chance B, Hammer DA, Therien MJ. 2005. Near-infrared-emissive polymersomes: Self-assembled soft matter for in vivo optical imaging. Proc Natl Acad Sci U S A 102(8):2922-2927.
31. Schadlich A, Caysa H, Mueller T, Tenambergen F, Rose C, Gopferich A, Kuntsche J, Mader K. 2011. Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: Impact of particle size and human xenograft tumor model. ACS Nano 5(11):8710-8720.
32. Louie A. 2010. Multimodality imaging probes: Design and challenges. Chem Rev 110(5):3146-3195.
33. Reul R, Tsapis N, Hillaireau H, Sancey L, Mura S, Recher M, Nicolas J, Coll JL, Fattal E. 2012. Near infrared labeling of PLGA for in vivo imaging of nanoparticles. Polym Chem 3(3):694-702.
34. Fernandez-Fernandez A, Manchanda R, McGoron AJ. 2011. Theranostic applications of nanomaterials in cancer: Drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol 165(7-8):1628-1651.
35. Vauthier C, Cabane B, Labarre D. 2008. How to concentrate nanoparticles and avoid aggregation? Eur J Pharm Biopharm 69(2):466-475.
36. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. 2006. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev 58(15):1688-1713.
37. Pham W, Choi Y, Weissleder R, Tung CH. 2004. Developing a peptide-based near-infrared molecular probe for protease sensing. Bioconjug Chem 15(6):1403-1407.
38. Hayden DM, Forsyth C, Keshavarzian A. 2011. The role of matrix metalloproteinases in intestinal epithelial wound healing during normal and inflammatory states. J Surg Res 168(2):315-324.
39. Di Girolamo N, Coroneo MT, Wakefield D. 2001. Active matrilysin (MMP-7) in human pterygia: Potential role in angiogenesis. Invest Ophthalmol Visual Sci 42(9):1963-1968.
40. Lindberg RL, De Groot CJ, Montagne L, Freitag P, van der Valk P, Kappos L, Leppert D. 2001. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124(Pt 9):1743-1753.
41. Mok H, Jeong H, Kim SJ, Chung BH. 2012. Indocyanine green encapsulated nanogels for hyaluronidase activatable and selective near infrared imaging of tumors and lymph nodes. Chem Commun (Camb) 48(69):8628-8630.
42. Tung CH, Mahmood U, Bredow S, Weissleder R. 2000. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res 60(17):4953-4958.
43. Johnson MD, Torri JA, Lippman ME, Dickson RB. 1993. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 53(4):873-877.
44. Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H. 2009. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm 6(2):386-395.
45. Lee H, Akers W, Bhushan K, Bloch S, Sudlow G, Tang R, Achilefu S. 2011. Near-infrared pH-activatable fluorescent probes for imaging primary and metastatic breast tumors. Bioconjug Chem 22(4):777-784.
46. Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, Nagano T, Watanabe T, Hasegawa A, Choyke PL, Kobayashi H. 2009. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 15(1):104-109.
47. Ishizuka M, Abe F, Sano Y, Takahashi K, Inoue K, Nakajima M, Kohda T, Komatsu N, Ogura S, Tanaka T. 2011. Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int Immunopharmacol 11(3):358-365.
48. Yoon JH, Yoon HE, Kim O, Kim SK, Ahn SG, Kang KW. 2012. The enhanced anti-cancer effect of hexenyl ester of 5-aminolaevulinic acid photodynamic therapy in adriamycin-resistant compared to non-resistant breast cancer cells. Lasers Surg Med 44(1):76-86.
49. Cohen R, Stammes MA, de Roos IH, Stigter-van Walsum M, Visser GW, van Dongen GA. 2011. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Res 1(1):31.
50. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. 2006. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392-401.
51. Ito S, Muguruma N, Kimura T, Yano H, Imoto Y, Okamoto K, Kaji M, Sano S, Nagao Y. 2006. Principle and clinical usefulness of the infrared fluorescence endoscopy. J Med Invest 53(1-2):1-8.
52. Troyan SL, Kianzad V, Gibbs-Strauss SL, Gioux S, Matsui A, Oketokoun R, Ngo L, Khamene A, Azar F, Frangioni JV. 2009. The FLARE intraoperative near-infrared fluorescence imaging system: A first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 16(10):2943-2952.
53. Khullar O, Frangioni JV, Grinstaff M, Colson YL. 2009. Image-guided sentinel lymph node mapping and nanotechnology-based nodal treatment in lung cancer using invisible near-infrared fluorescent light. Semin Thorac Cardiovasc Surg 21(4):309-315.
54. Wu F, Tamhane M, Morris ME. 2012. Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. AAPS J 14(2):252-261.
55. Gobin AM, Moon JJ, West JL. 2008. EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells. Int J Nanomedicine 3(3):351-358.
56. Moon HK, Lee SH, Choi HC. 2009. In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. ACS Nano 3(11):3707-3713.
57. Zheng X, Xing D, Zhou F, Wu B, Chen WR. 2011. Indocyanine green-containing nanostructure as near infrared dual-functional targeting probes for optical imaging and photothermal therapy. Mol Pharm 8(2):447-456.
58. Zheng X, Zhou F, Wu B, Chen WR, Xing D. 2012. Enhanced tumor treatment using biofunctional indocyanine green-containing nanostructure by intratumoral or intravenous injection. Mol Pharm 9(3):514-522.
59. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751-760.
60. Ghosh P, Han G, De M, Kim CK, Rotello VM. 2008. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60(11):1307-1315.
61. Tam JM, Tam JO, Murthy A, Ingram DR, Ma LL, Travis K, Johnston KP, Sokolov KV. 2010. Controlled assembly of biodegradable plasmonic nanoclusters for near-infrared imaging and therapeutic applications. ACS Nano 4(4):2178-2184.
62. Chen WR, Adams RL, Higgins AK, Bartels KE, Nordquist RE. 1996. Photothermal effects on murine mammary tumors using indocyanine green and an 808-nm diode laser: An in vivo efficacy study. Cancer Lett 98(2):169-173.
63. Shafirstein G, Baumler W, Hennings LJ, Siegel ER, Friedman R, Moreno MA, Webber J, Jackson C, Griffin RJ. 2012. Indocyanine green enhanced near-infrared laser treatment of murine mammary carcinoma. Int J Cancer 130(5):1208-1215.
64. Szeimies RM, Lorenzen T, Karrer S, Abels C, Plettenberg A. 2001. [Photochemotherapy of cutaneous AIDS-associated Kaposi sarcoma with indocyanine green and laser light]. Hautarzt 52(4):322-326.
65. Abels C, Karrer S, Baumler W, Goetz AE, Landthaler M, Szeimies RM. 1998. Indocyanine green and laser light for the treatment of AIDS-associated cutaneous Kaposi's sarcoma. Br J Cancer 77(6):1021-1024.
66. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. 2008. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci 23(3):217-228.
67. Kirchherr AK, Briel A, Mader K. 2009. Stabilization of indocyanine green by encapsulation within micellar systems. Mol Pharm 6(2):480-491.
68. Zhang C, Wang S, Xiao J, Tan X, Zhu Y, Su Y, Cheng T, Shi C. 2010. Sentinel lymph node mapping by a near-infrared fluorescent heptamethine dye. Biomaterials 31(7):1911-1917.
69. Tantra R, Knight A. 2011. Cellular uptake and intracellular fate of engineered nanoparticles: A review on the application of imaging techniques. Nanotoxicology 5(3):381-392.
70. Desai N. 2012. Challenges in development of nanoparticle-based therapeutics. AAPS J 14(2):282-295.
71. Cho K, Wang X, Nie S, Chen ZG, Shin DM. 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14(5):1310-1316.
72. 188Re-labeled micelles containing a cyanine-type photosensitizer. ACS Nano 5(7):5594-5607.
73. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, Chan WC, Cao W, Wang LV, Zheng G. 2011. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater 10(4):324-332.
74. Yu J, Javier D, Yaseen MA, Nitin N, Richards-Kortum R, Anvari B, Wong MS. 2010. Self-assembly synthesis, tumor cell targeting, and photothermal capabilities of antibody-coated indocyanine green nanocapsules. J Am Chem Soc 132(6):1929-1938.
75. Kessel D, Oleinick NL. 2010. Photodynamic therapy and cell death pathways. Methods Mol Biol 635:35-46.
76. Kochevar IE, Redmond RW. 2000. Photosensitized production of singlet oxygen. Methods Enzymol 319:20-28.
77. Senge MO, Brandt JC. 2011. Temoporfin (Foscan(R), 5, 10, 15, 20-tetra(m-hydroxyphenyl)chlorin)-A second-gen-eration photosensitizer. Photochem Photobiol 87(6):1240-1296.
78. Celli JP, Solban N, Liang A, Pereira SP, Hasan T. 2011. Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg Med 43(7):565-574.
79. Sharma T, Shah N, Gopal L, Shanmugam MP, Bhende P, Bhende M, Shetty NS, Sukumar B. 2004. Indocyanine green dye-enhanced transpupillary thermotherapy of classic subfoveal choroidal neovascularization. Ophthalmic Surg Lasers Imaging 35(3):197-206.
80. Kamal A, Watts AR, Rennie IG. 2000. Indocyanine green enhanced transpupillary thermotherapy of circumscribed choroidal haemangioma. Eye (Lond) 14 Pt 5:701-705.
81. Liggett PE, Lavaque AJ, Chaudhry NA, Jablon EP, Quiroz-Mercado H. 2005. Preliminary results of combined simultaneous transpupillary thermotherapy and ICG-based photodynamic therapy for choroidal melanoma. Ophthalmic Surg Lasers Imaging 36(6):463-470.
82. Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S. 2008. Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 10(3):148-154.
83. Sunar U, Rohrbach D, Rigual N, Tracy E, Keymel K, Cooper MT, Baumann H, Henderson BH. 2010. Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: A case report. Opt Express 18(14):14969-14978.
84. Shackley DC, Whitehurst C, Moore JV, George NJ, Betts CD, Clarke NW. 2000. Light penetration in bladder tissue: Implications for the intravesical photodynamic therapy of bladder tumours. BJU Int 86(6):638-643.
85. Triesscheijn M, Baas P, Schellens JH, Stewart FA. 2006. Photodynamic therapy in oncology. Oncologist 11(9):1034-1044.
86. Menon C, Kutney SN, Lehr SC, Hendren SK, Busch TM, Hahn SM, Fraker DL. 2001. Vascularity and uptake of photosensitizer in small human tumor nodules: Implications for intraperitoneal photodynamic therapy. Clin Cancer Res 7(12):3904-3911.
87. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. 2011. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 17(12):1685-1691.
88. Young SW, Woodburn KW, Wright M, Mody TD, Fan Q, Sessler JL, Dow WC, Miller RA. 1996. Lutetium texaphyrin (PCI-0123): A near-infrared, water-soluble photosensitizer. Photochem Photobiol 63(6):892-897.
89. Kuo WS, Chang YT, Cho KC, Chiu KC, Lien CH, Yeh CS, Chen SJ. 2012. Gold nanomaterials conjugated with indocyanine green for dual-modality photodynamic and photothermal therapy. Biomaterials 33(11):3270-3278.
90. Funayama T, Sakane M, Abe T, Ochiai N. 2012. Photodynamic therapy with indocyanine green injection and near-infrared light irradiation has phototoxic effects and delays paralysis in spinal metastasis. Photomed Laser Surg 30(1):47-53.
91. Barth BM, EIA, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP, Jr., Claxton DF, Kester M. 2011. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano 5(7):5325-5337.
92. Dolmans DE, Kadambi A, Hill JS, Flores KR, Gerber JN, Walker JP, Borel Rinkes IH, Jain RK, Fukumura D. 2002. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res 62(15):4289-4294.
93. Schmidt MH, Meyer GA, Reichert KW, Cheng J, Krouwer HG, Ozker K, Whelan HT. 2004. Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. J Neurooncol 67(1-2):201-207.
94. Savellano MD, Hasan T. 2005. Photochemical targeting of epidermal growth factor receptor: a mechanistic study. Clin Cancer Res 11(4):1658-1668.
95. Choi Y, McCarthy JR, Weissleder R, Tung CH. 2006. Conjugation of a photosensitizer to an oligoarginine-based cell-penetrating peptide increases the efficacy of photodynamic therapy. ChemMedChem 1(4):458-463.
96. Liu T, Wu LY, Choi JK, Berkman CE. 2010. Targeted photodynamic therapy for prostate cancer: Inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol 36(4):777-784.
97. Hamblin MR, Newman EL. 1994. Photosensitizer targeting in photodynamic therapy. I. Conjugates of haematoporphyrin with albumin and transferrin. J Photochem Photobiol B 26(1):45-56.
98. Hamblin MR, Newman EL. 1994. Photosensitizer targeting in photodynamic therapy. II. Conjugates of haematoporphyrin with serum lipoproteins. J Photochem Photobiol B 26(2):147-157.
99. Gravier J, Schneider R, Frochot C, Bastogne T, Schmitt F, Didelon J, Guillemin F, Barberi-Heyob M. 2008. Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. Synthesis and in vivo delivery studies. J Med Chem 51(13):3867-3877.
100. Schneider R, Schmitt F, Frochot C, Fort Y, Lourette N, Guillemin F, Muller JF, Barberi-Heyob M. 2005. Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy. Bioorg Med Chem 13(8):2799-2808.
101. Sudimack J, Lee RJ. 2000. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41(2):147-162.
102. Frochot C, Di Stasio B, Vanderesse R, Belgy MJ, Dodeller M, Guillemin F, Viriot ML, Barberi-Heyob M. 2007. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. Bioorg Chem 35(3):205-220.
103. Mukhopadhyay S, Barnes CM, Haskel A, Short SM, Barnes KR, Lippard SJ. 2008. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem 19(1):39-49.
104. Conway CL, Walker I, Bell A, Roberts DJ, Brown SB, Vernon DI. 2008. In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy. Photochem Photobiol Sci 7(3):290-298.
105. Tirand L, Frochot C, Vanderesse R, Thomas N, Trinquet E, Pinel S, Viriot ML, Guillemin F, Barberi-Heyob M. 2006. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Control Release 111(1-2):153-164.
106. Yang X, Huang J, Wang K, Li W, Cui L, Li X. 2011. Angiogenin-mediated photosensitizer-aptamer conjugate for photodynamic therapy. ChemMedChem 6(10):1778-1780.
107. Mallikaratchy P, Tang Z, Tan W. 2008. Cell specific aptamer-photosensitizer conjugates as a molecular tool in photodynamic therapy. ChemMedChem 3(3):425-428.
108. Shieh YA, Yang SJ, Wei MF, Shieh MJ. 2010. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 4(3):1433-1442.
109. Lee YE, Kopelman R. 2011. Polymeric nanoparticles for photodynamic therapy. Methods Mol Biol 726:151-178.
110. Chouikrat R, Seve A, Vanderesse R, Benachour H, Barberi-Heyob M, Richeter S, Raehm L, Durand JO, Verelst M, Frochot C. 2012. Non polymeric nanoparticles for photodynamic therapy applications: Recent developments. Curr Med Chem 19(6):781-792.
111. Huang P, Xu C, Lin J, Wang C, Wang X, Zhang C, Zhou X, Guo S, Cui D. 2011. Folic acid-conjugated graphene oxide loaded with photosensitizers for targeting photodynamic therapy. Theranostics 1:240-250.
112. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, Kim G, Koo YE, Woolliscroft MJ, Sugai JV, Johnson TD, Philbert MA, Kopelman R, Rehemtulla A, Ross BD. 2006. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 12(22):6677-6686.
113. Obaid G, Chambrier I, Cook MJ, Russell DA. 2012. Targeting the oncofetal Thomsen-Friedenreich disaccharide using jacalin-PEG phthalocyanine gold nanoparticles for photodynamic cancer therapy. Angew Chem Int Ed Engl 51(25):6158-6162.
114. Zhou A, Wei Y, Wu B, Chen Q, Xing D. 2012. Pyropheophorbide A and c(RGDyK) comodified chitosan-wrapped upconversion nanoparticle for targeted near-infrared photodynamic therapy. Mol Pharm 9(6):1580-1589.
115. Stuchinskaya T, Moreno M, Cook MJ, Edwards DR, Russell DA. 2011. Targeted photodynamic therapy of breast cancer cells using antibody-phthalocyanine-gold nanoparticle conjugates. Photochem Photobiol Sci 10(5):822-831.
116. Gloi AM, Beck E. 2003. Threshold dose of three photosensitizers in dogs with spontaneous tumors. Vet Ther 4(3):269-278.
117. Dolmans DE, Fukumura D, Jain RK. 2003. Photodynamic therapy for cancer. Nat Rev Cancer 3(5):380-387.
118. Baas P, van Mansom I, van Tinteren H, Stewart FA, van Zandwijk N. 1995. Effect of N-acetylcysteine on photofrin-induced skin photosensitivity in patients. Lasers Surg Med 16(4):359-367.
119. Lovell JF, Chen J, Jarvi MT, Cao WG, Allen AD, Liu Y, Tidwell TT, Wilson BC, Zheng G. 2009. FRET quenching of photosensitizer singlet oxygen generation. J Phys Chem B 113(10):3203-3211.
120. Wang J, Zhu G, You M, Song E, Shukoor MI, Zhang K, Altman MB, Chen Y, Zhu Z, Huang CZ, Tan W. 2012. Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy. ACS Nano 6(6):5070-5077.
121. Jang B, Park JY, Tung CH, Kim IH, Choi Y. 2011. Gold nanorod-photosensitizer complex for near-infrared fluorescence imaging and photodynamic/photothermal therapy in vivo. ACS Nano 5(2):1086-1094.
122. Tian B, Wang C, Zhang S, Feng L, Liu Z. 2011. Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide. ACS Nano 5(9):7000-7009.
123. Choi Y, Weissleder R, Tung CH. 2006. Protease-mediated phototoxicity of a polylysine-chlorin(E6) conjugate. ChemMedChem 1(7):698-701.
124. Choi Y, Weissleder R, Tung CH. 2006. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res 66(14):7225-7229.
125. Bae BC, Na K. 2010. Self-quenching polysaccharide-based nanogels of pullulan/folate-photosensitizer conjugates for photodynamic therapy. Biomaterials 31(24):6325-6335.
126. Podgorski I, Sloane BF. 2003. Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp (70):263-276.
127. Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G. 2009. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. J Med Chem 52(2):358-368.
128. Chen J, Stefflova K, Niedre MJ, Wilson BC, Chance B, Glickson JD, Zheng G. 2004. Protease-triggered photosensitizing beacon based on singlet oxygen quenching and activation. J Am Chem Soc 126(37):11450-11451.
129. Yoon HY, Koo H, Choi KY, Lee SJ, Kim K, Kwon IC, Leary JF, Park K, Yuk SH, Park JH, Choi K. 2012. Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 33(15):3980-3989.